Completed PHASE3 INTERVENTIONAL 2-arm NCT01960348

APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis

APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)

Sponsor: Alnylam Pharmaceuticals

Conditions Amyloid Neuropathies Amyloid Neuropathies, Familial Amyloidosis, Hereditary Amyloidosis, Hereditary, Transthyretin-Related Familial Amyloid Polyneuropathies TTR-mediated Amyloidosis

Interventions Sterile Normal Saline (0.9% NaCl) patisiran (ALN-TTR02)

Updated 15 times since 2017 Last updated: Apr 17, 2024 Started: Nov 30, 2013 Primary completion: Aug 31, 2017 Completion: Aug 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Amyloid Neuropathies and Amyloid Neuropathies, Familial, this trial is completed. The trial is conducted by Alnylam Pharmaceuticals and has accumulated 15 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

15 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
May 2024 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — May 2024 [monthly]

Completed PHASE3

▶ Show 10 earlier versions

Jan 2019 — Jan 2021 [monthly]

Completed PHASE3
Dec 2018 — Jan 2019 [monthly]

Completed PHASE3
Nov 2018 — Dec 2018 [monthly]

Completed PHASE3
Oct 2018 — Nov 2018 [monthly]

Completed PHASE3
Jun 2018 — Oct 2018 [monthly]

Completed PHASE3
Feb 2018 — Jun 2018 [monthly]

Completed PHASE3
Jan 2018 — Feb 2018 [monthly]

Completed PHASE3
Oct 2017 — Jan 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Feb 2017 — Oct 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Nov 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alnylam Pharmaceuticals

Data source: Alnylam Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aichi, Japan , Baltimore, United States , Barcelona, Spain , Boston, United States , Bourdeaux, France , Buenos Aires, Argentina , Chicago, United States , Créteil, France , Denver, United States , Detroit, United States and 39 more locations